MetaVia Doses First Patient in Part 3 of Phase 1 Trial for Dual GLP-1/Glucagon Analog DA-1726

MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog designed to target both GLP-1 and glucagon receptors. This advancement signifies continued progress in the company's clinical development pipeline for a potentially significant metabolic therapeutic. Part 3 of the trial is structured with two 16-week titration cohorts, aiming to assess various dose-escalation strategies to safely reach higher target doses and enhance the drug's tolerability profile. This step is crucial for optimizing the therapeutic potential of DA-1726 as it moves through early-stage development.